课题基金 / 基金详情

Susceptibility of antigen-specific CD4 T cells to HIV: implications for HIV vacci

Susceptibility of antigen-specific CD4 T cells to HIV: implications for HIV vacci
抗原特异性 CD4 T 细胞对 HIV 的敏感性:对 HIV 疫苗的影响
批准号:
9070878
负责人:
Haitao Hu
金额:
$13.95万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-02-05 至 2018-01-31

项目摘要

项目成果

Haitao Hu的其他基金

相似基金

相关文献

中文摘要
翻译
产品说明:更好地理解HIV感染的发病机制的一个中心问题是记忆性CD 4 T细胞如何被HIV感染并逐渐耗尽。目前对HIV感染对不同病原体或抗原特异性的CD 4 T细胞的影响知之甚少。探索这一领域对于更好地理解不同的时间安排是重要的。 艾滋病患者的机会性感染。此外,鉴定对HIV具有“抗性”的疫苗特异性CD 4 T细胞的功能群体对于HIV疫苗设计至关重要。 我们建立了一个新的系统来研究抗原特异性CD 4 T细胞对HIV的易感性,并发现不同抗原特异性CD 4 T细胞对HIV感染的易感性存在显著差异。我们的初步数据显示,与破伤风类毒素(TT)和白色念珠菌(念珠菌)特异性的CD 4 T细胞相比,这是允许艾滋病毒,巨细胞病毒(CMV)特异性的CD 4 T细胞是高度耐药的R5和X4艾滋病毒与后进入艾滋病毒的限制。我们的微阵列分析确定了一种新的病毒RNA传感器,IFIT 1,是高度上调CMV特异性CD 4 T细胞。重要的是,在我们正在进行的实验中,我们表明IFIT 1的过表达显著抑制A3 R5 CD 4 T细胞系中的HIV感染。基于已经产生的数据,我们假设IFIT 1可以抑制HIV在人原代CD 4 T细胞中的感染,并且IFIT 1的差异表达调节抗原特异性CD 4 T细胞对HIV的容许性。 我们进一步建议将新的系统和观察扩展到临床HIV疫苗研究。HIV优先感染疫苗产生的CD 4 T细胞会降低疫苗诱导的免疫效率。我们的假设是,保护性HIV疫苗将诱导一种疫苗特异性CD 4 T细胞,这些细胞对HIV“不容易易感”,并且不同的候选HIV疫苗(例如不同的载体)诱导疫苗特异性CD 4 T细胞的不同表型,这可能显著影响其对HIV的敏感性。我们会检测外周血 来自三个已完成的HIV疫苗试验的单核细胞样本:RV 144(ALVAC)、RV 158(MVA)和IPVC 001(Ad 26)。我们的假设将在2个特定目的中得到解决:1)确定IFIT 1在调节人类抗原特异性CD 4 T细胞对HIV的易感性中的作用,并进一步探索IFIT 1抑制HIV的机制; 2)研究不同HIV疫苗诱导的抗原特异性CD 4 T细胞对HIV感染的易感性以及HIV疫苗试验中的相关表型。 这些研究是探索性的,但有望为以下方面提供新的见解:1)了解艾滋病患者CMV特异性T细胞免疫持续存在的机制; 2)确定一种新的抗HIV分子,其抑制机制/途径以前未被确定,可能导致开发新的HIV治疗方法; 3)更好地理解疫苗产生的CD 4 T细胞免疫的质量,并提供关于是否以及如何通过HIV疫苗诱导功能性的“HIV抗性”CD 4 T细胞的概念知识的证明。
英文摘要
DESCRIPTION: A central question to better understanding the pathogenesis of HIV infection is how memory CD4 T cells are infected and progressively depleted by HIV. Little is currently known about the impact of HIV infection on CD4 T cells of different pathogen or antigen specificities. Exploring this area is important for better understanding of the timing of different opportunistic infections in AIDS patients. In addition, identification of a functional population o vaccine-specific CD4 T cells that is "resistant" to HIV is critical for HIV vaccine design. We have established a novel system for studying the susceptibility of antigen-specific CD4 T cells to HIV, and have found that different antigen-specific CD4 T cells manifest marked differences in susceptibility to HIV infection. Our preliminary data show that compared to CD4 T cells specific to tetanus toxoid (TT) and Candida albicans (Candida), which are permissive to HIV, cytomegalovirus (CMV)-specific CD4 T cells are highly resistant to both R5 and X4 HIV with post-entry HIV restriction. Our microarray analysis identified a novel viral RNA sensor, IFIT1 that is highly upregulated in CMV-specific CD4 T cells. Of importance, in our ongoing experiments, we show that over-expression of IFIT1 significantly inhibits HIV infection in A3R5 CD4 T cell line. Based on data already generated, we hypothesize that IFIT1 can inhibit HIV infection in human primary CD4 T cells and differential expression of IFIT1 regulates the permissiveness of antigen-specific CD4 T cells to HIV. We further propose to extend the novel system and observations to clinical HIV vaccine studies. Preferential infection of vaccine-generated CD4 T cells by HIV reduces the efficiency of vaccine-induced immunity. Our hypothesis is that a protective HIV vaccine would induce a type of vaccine-specific CD4 T cells that are "not readily susceptible" to HIV, and that different candidate HIV vaccines (e.g. different vectors) induce distinct phenotypes of vaccine-specific CD4 T cells that may significantly impact their sensitivities to HIV. We will test peripheral blood mononuclear cell samples from three completed HIV vaccine trials: RV144 (ALVAC), RV158 (MVA) and IPVC001 (Ad26). Our hypotheses will be addressed in 2 Specific Aims: 1) To determine the role of IFIT1 in regulating the susceptibility of human antigen-specific CD4 T cells to HIV and to further explore the mechanisms for inhibition of HIV by IFIT1; 2) To investigate the susceptibilities of different HIV vaccine-induced, antigen-specific CD4 T cells to HIV infection and the associated phenotypes in HIV vaccine trials. The proposed studies are exploratory, but expected to provide new insights to: 1) understand the mechanisms for the persistence of CMV-specific T cell immunity in AIDS patients; 2) identify a novel anti-HIV molecule with previously unidentified inhibitory mechanisms/pathways that could lead to the development of novel HIV therapies; 3) better understand the quality of vaccine-generated CD4 T cell immunity and to provide proof of concept knowledge on whether and how to induce functional, "HIV-resistant" CD4 T cells by an HIV vaccine.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI: 10.4049/jimmunol.1700698
发表时间: 2017-11-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Liu F, Niu Q, Fan X, Liu C, Zhang J, Wei Z, Hou W, Kanneganti TD, Robb ML, Kim JH, Michael NL, Sun J, Soong L, Hu H]
通讯作者: Hu H
DOI: 10.1586/14760584.2016.1147354
发表时间: 2016-06
期刊: Expert review of vaccines
影响因子: 6.2
作者: [Hu H, Liu F, Kim J, Ratto-Kim S]
通讯作者: Ratto-Kim S
Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
非小细胞肺癌脑转移患者的突变状态和切除后生存:生物标志物驱动治疗的影响。
DOI: 10.3171/2020.10.jns201787
发表时间: 2022
期刊: Journal of neurosurgery
影响因子: 4.1
作者: [Shah,PavanP, Franke,JenniferL, Medikonda,Ravi, Jackson,ChristopherM, Srivastava,Siddhartha, Choi,John, Forde,PatrickM, Brahmer,JulieR, Ettinger,DavidS, Feliciano,JosephineL, Levy,BenjaminP, Marrone,KristenA, Naidoo,Jarushka, Redmond,]
通讯作者: Redmond,
Modulation of BRD4 to epigenetically suppress HIV
Modulation of BRD4 to epigenetically suppress HIV
Modulation of BRD4 to epigenetically suppress HIV
In vitro and in vivo analysis of susceptibility of Ad26 vector-induced CD4 T cells to HIV/SIV
海外基金